Loading...

Christopher Stauffer, MD

Title(s)Assistant Professor, Psychiatry
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    San Francisco VA Medical Center/UCSFFellowship2016Psychiatry Research
    University of California, San FranciscoResidency2014Adult General Psychiatry
    Oregon Health & Science UniversityM.D.2010Medicine
    Collapse Awards and Honors
    Association for Multidisciplinary Education and Research in Substance use and Addiction2018Best Research Abstract - Runner-Up

    Collapse Overview 
    Collapse Overview
    Chris Stauffer received his MD from Oregon Health & Science University in 2010 and completed his Adult Psychiatry Residency at the University of California, San Francisco (UCSF) in 2014. He also completed a post-graduate Psychiatry Research Fellowship at the San Francisco VA Medical Center (SFVAMC). He is currently Assistant Adjunct Professor at UCSF, is the recipient of a VA Career Development Award, and is dual board-certified in Psychiatry and Addiction Medicine. Clinically, he specializes in the treatment of substance use disorders and posttraumatic stress disorder. His research combines clinical psychiatry, social neuroscience, and attachment theory; specifically, he investigates the use of social psychopharmacology - such as oxytocin, MDMA, and psilocybin - as an adjunct to psychotherapy for substance use disorders and PTSD. Dr. Stauffer is the Principal Investigator of several clinical trials using intranasal oxytocin to enhance treatment for substance use disorders. He is sub-investigator and study therapist for the Phase 3 trials of MDMA-assisted psychotherapy for severe PTSD funded by the Multidisciplinary Association of Psychedelic Studies (MAPS) and for a Phase 2 trial of psilocybin-enhanced psychotherapy for demoralization in longterm AIDS survivors, both taking place at UCSF.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse Student Projects

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Trope A, Anderson BT, Hooker AR, Glick G, Stauffer C, Woolley JD. Psychedelic-Assisted Group Therapy: A Systematic Review. J Psychoactive Drugs. 2019 Apr 05; 1-15. PMID: 30950777.
      View in: PubMed
    2. Stauffer CS, Moschetto JM, McKernan SM, Hsiang E, Borsari B, Woolley JD. Oxytocin-enhanced motivational interviewing group therapy for methamphetamine use disorder in men who have sex with men: study protocol for a randomized controlled trial. Trials. 2019 Feb 21; 20(1):145. PMID: 30791944.
      View in: PubMed
    3. Stauffer CS, Dobberteen L, Woolley JD. American Alcohol Photo Stimuli (AAPS): A standardized set of alcohol and matched non-alcohol images. Am J Drug Alcohol Abuse. 2017 11; 43(6):647-655. PMID: 27893279.
      View in: PubMed
    4. Stauffer CS, Musinipally V, Suen A, Lynch KL, Shapiro B, Woolley JD. A two-week pilot study of intranasal oxytocin for cocaine-dependent individuals receiving methadone maintenance treatment for opioid use disorder. Addict Res Theory. 2016; 24(6):490-498. PMID: 28503120.
      View in: PubMed
    5. Woolley JD, Arcuni PA, Stauffer CS, Fulford D, Carson DS, Batki S, Vinogradov S. The effects of intranasal oxytocin in opioid-dependent individuals and healthy control subjects: a pilot study. Psychopharmacology (Berl). 2016 07; 233(13):2571-80. PMID: 27137199.
      View in: PubMed
    6. Stauffer CS, Woolley JD. Can we bottle psychosocial treatments for addiction? The role of oxytocin. J Clin Psychiatry. 2014 Sep; 75(9):1028-9. PMID: 25295428.
      View in: PubMed